Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis

Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis

Abstract Background Sodium-glucose co-transporter-2 inhibitors (SGLT-2is) are licenced for initiation for glucose lowering in people with type 2 diabetes (T2DM) with an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2). However, recent trial data have shown that these medications have...

Full description

Bibliographic Details
Main Authors: William Hinton, Michael D. Feher, Neil Munro, Mark Joy, Simon de Lusignan
Format: Article
Language:English
Published: BMC 2021-06-01
Series:Cardiovascular Diabetology
Subjects:
Type 2
Diabetes Mellitus
Heart Failure
Kidney Function Tests
Computerized Medical Record Systems
Sodium-Glucose Transporter 2 Inhibitors
Online Access:https://doi.org/10.1186/s12933-021-01316-4

Internet

https://doi.org/10.1186/s12933-021-01316-4

Similar Items